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Inhibition of mTOR complex 1 (mTORC1) with rapamy-
cin leads to phosphorylation of AKT in some cancer cells
with unknown biological consequences. A mechanism
involving insulin receptor substrate (IRS) and phosphati-
dylinositol 3-kinase (PI3K) leading to increased AKT
phosphorylation has been described. For melanoma, it is
unknown, whether this feedback loop plays a role,
although preliminary clinical data indicate poor activity
of rapalogues in melanoma. Here, we report that treat-
ment of melanoma cells with rapamycin resulted in
strong and long lasting AKT phosphorylation, but had lit-
tle or no effects on cell viability, cell cycle arrest or apop-
tosis. Combined PI3K/mTOR inhibition with LY294002
had strong effects on these parameters, but also led to
increased phospho-AKT levels after prolonged treatment.
In contrast to the single treatments, combination of
rapamycin plus LY294002 was able to suppress AKT phos-
phorylation even after prolonged treatment. Inhibition of
mTOR complex 2 (mTORC2) using RNAi led to reduced
levels of p-AKT, also under conditions when mTORC1
was inhibited. PTEN mutant melanoma cells showed
slightly increased levels of AKT phosphorylation com-
pared to PTEN wild-type cells. Thus, our results indicate
that mTORC1 inhibition with specific inhibitors such as
rapamycin as well as with multi-target inhibitors such as
LY294002 can lead to AKT phosphorylation in melanoma
cells via mTORC2, but without significant influence on
treatment efficacy in vitro.
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